AnnexVIR
| Reference number | |
| Coordinator | Annexin Pharmaceuticals AB |
| Funding from Vinnova | SEK 500 000 |
| Project duration | June 2015 - September 2015 |
| Status | Completed |
Important results from the project
The objective is to assess the therapeutic potential of Annexin A5 for treatment of hemorrhagic fevers. The Project has been performed according to plan and interesting results have been obtained.
Expected long term effects
In vitro studies have demonstrated an effect of Annexin A5 on replication of certain viruses. The work has led to planning and excecution of additional studies.
Approach and implementation
The studies have been performed in collaboration with both national and international universities and research organizations. The Project has been performed according to plan.